Insulet (PODD) Receives a Buy from Leerink Partners

Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Insulet (PODDResearch Report) on January 24 and set a price target of $275.00. The company’s shares closed last Thursday at $252.81.

According to, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insulet with a $304.17 average price target, implying a 22.0% upside from current levels. In a report issued on February 2, UBS also upgraded the stock to Buy with a $325.00 price target.

See the top stocks recommended by analysts >>

Based on Insulet’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $276 million and net profit of $12.6 million. In comparison, last year the company earned revenue of $234 million and had a net profit of $11.6 million.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PODD in relation to earlier this year. Most recently, in December 2021, Shacey Petrovic, the President & CEO of PODD bought 2,163 shares for a total of $99,974.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Read More on PODD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More